- Home
- MRLN vs FHTX Comparison
MRLN vs FHTX Comparison
Compare MRLN & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MRLN | FHTX |
|---|---|---|
| Founded | 2018 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 415.1M | 419.9M |
| IPO Year | 2024 | 2020 |
Fundamental Metrics
Financial Performance| Metric | MRLN | FHTX |
|---|---|---|
| Price | $3.36 | $6.85 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | ★ $25.00 | $11.50 |
| AVG Volume (30 Days) | ★ 1.1M | 284.5K |
| Earning Date | 10-28-2021 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.32 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $30,909,000.00 |
| Revenue This Year | N/A | $8.89 |
| Revenue Next Year | N/A | $20.13 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 36.75 |
| 52 Week Low | $3.16 | $3.27 |
| 52 Week High | $17.00 | $7.61 |
Technical Indicators
Market Signals| Indicator | MRLN | FHTX |
|---|---|---|
| Relative Strength Index (RSI) | 39.40 | 68.92 |
| Support Level | $3.27 | $4.21 |
| Resistance Level | $4.67 | N/A |
| Average True Range (ATR) | 0.32 | 0.52 |
| MACD | -0.02 | 0.07 |
| Stochastic Oscillator | 16.56 | 78.13 |
Price Performance
Historical ComparisonAbout MRLN Merlin Inc. Common Stock
Merlin Inc is focused on developing autonomous flight software for legacy and next-generation airborne systems. Its aircraft-agnostic, AI-based software supports takeoff-to-landing autonomous operations for military and civil aviation programs. The company aims to build an AI-based operating software platform intended to support autonomous flight operations across a range of aircraft types.
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.